Karl R. Gibson

Karl R. Gibson

Auto-generated profile, based on publicly available information

Karl R. Gibson

Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
PAParis Avgoustou
Paris Avgoustou
Ameera JailaniAmeera Jailani
Ameera Jailani
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
GRGareth Owain Richards
Gareth Owain Richards

5 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
Ameera JailaniAmeera Jailani
Ameera Jailani
PAParis Avgoustou
Paris Avgoustou
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
JHJoe Harrity
Joe Harrity
Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.